Committed to developing innovative cancer therapies, Dendreon is evaluating a variety of therapeutic approaches. While each approach employs a distinct mechanism of action to destroy cancer cells, they all share a common attribute–a targeted therapy platform that addresses an unmet medical need, improves the lives of patients and provides a favorable safety and tolerability profile.
Dendreon’s research and development program is exploring the application of active cellular immunotherapies (ACIs) and small molecules to the potential treatment of a variety of cancers.
Print page
Email page